RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Anyone think it was odd Below are few companies in the space which is innovative versus conventional cancer therapies.
As for the report my version was very simplistic compared to Jim’s, the advantage of simple language used is just about anybody from age of 18 only with high school degree can understand it. The various oncology financial opportunities (market caps in dollar amount) were from information available online. Since then as per the Fireside chat:
They send all 6 cancer results so the FDA gave them the fast track designation as they had enough information to be given that designation based on only animal research which sounds like the agency liked their MOA.
If the trial shows safety and efficacy in P1 cancer, the 2 and 3 will move a lot faster given unmet need.
50 to 60 percent of patients who died of cancer had over expressed sortilin.
$12 billion revenue for advanced stage cancer which can be much higher if they start treating early stage cancers.
They will make announcement whenever they have data available to the whole world.
Cash is $70 million.
Sort1 technology has no competition, with IP protection.
Sutro Biopharma, Inc. (STRO)
Market Cap 1.101B
ADC (Antibody Drug Conjugate) phase1 company for STRO-002/003 series (which they kept the commercializing right for that particular technology), they also have another phase1 ADC trial and 4 other preclinical cancer programs which they gave up the commercializing rights to other companies to raise cash. No commercialized drug and with inferior ADC technology.
Cash, Cash Equivalents and Marketable Securities, as of September 30, 2020, Sutro had cash, cash equivalents and marketable securities of $202.4 million.
Sutro recorded net income of $17.1 million and $27.4 million for the three and nine months
Ended September 30, 2020, respectively, due primarily to an unrealized gain related to its
Vaxcyte common stock of $78.6 million during 2020.
ADC Therapeutics
Market Cap US $2.338B
ADC phase1/starting phase2 company, their ADCT series are in range of preclinicals to completed phase1.
Cash and cash equivalents were $494.4 million as of September 30, 2020, compared to $115.6 million as of December 31, 2019.The increase is due to public offering in 2020. No commercial drugs with inferior ADC technology.
Oncopeptides AB
Market Cap US &11.421B
PDC phase3 company, their drug Melflufen a Peptide–Drug Conjugate for the Treatment of Multiple Myeloma and potential combination cancer treatment.
Cash flow negative and issued offering few times in the last year. As of September 30, 2020, cash and cash equivalents amounted to SEK 1,251.6 M (US $151M). No commercialized drug